These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19660388)

  • 1. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
    Reesink HJ; Surie S; Kloek JJ; Tan HL; Tepaske R; Fedullo PF; Bresser P
    J Thorac Cardiovasc Surg; 2010 Jan; 139(1):85-91. PubMed ID: 19660388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
    Reesink HJ; van der Plas MN; Verhey NE; van Steenwijk RP; Kloek JJ; Bresser P
    J Thorac Cardiovasc Surg; 2007 Feb; 133(2):510-6. PubMed ID: 17258590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study.
    Hughes RJ; Jais X; Bonderman D; Suntharalingam J; Humbert M; Lang I; Simonneau G; Pepke-Zaba J
    Eur Respir J; 2006 Jul; 28(1):138-43. PubMed ID: 16611652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan for chronic thromboembolic pulmonary hypertension.
    Confalonieri M; Kodric M; Longo C; Vassallo FG
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.
    Hefke T; Zittermann A; Fuchs U; Schulte-Eistrup S; Gummert JF; Schulz U
    Thorac Cardiovasc Surg; 2012 Feb; 60(1):26-34. PubMed ID: 21432755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.
    Surie S; Reesink HJ; Marcus JT; van der Plas MN; Kloek JJ; Vonk-Noordegraaf A; Bresser P
    Clin Cardiol; 2013 Nov; 36(11):698-703. PubMed ID: 24037998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosentan for patients with chronic thromboembolic pulmonary hypertension.
    Vassallo FG; Kodric M; Scarduelli C; Harari S; Potena A; Scarda A; Piattella M; Cassandro R; Confalonieri M
    Eur J Intern Med; 2009 Jan; 20(1):24-9. PubMed ID: 19237088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term bosentan in chronic thromboembolic pulmonary hypertension.
    Seyfarth HJ; Hammerschmidt S; Pankau H; Winkler J; Wirtz H
    Respiration; 2007; 74(3):287-92. PubMed ID: 16699254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
    Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G
    Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension.
    Thistlethwaite PA; Kemp A; Du L; Madani MM; Jamieson SW
    J Thorac Cardiovasc Surg; 2006 Feb; 131(2):307-13. PubMed ID: 16434258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
    McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
    Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
    Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
    Wilkins MR; Paul GA; Strange JW; Tunariu N; Gin-Sing W; Banya WA; Westwood MA; Stefanidis A; Ng LL; Pennell DJ; Mohiaddin RH; Nihoyannopoulos P; Gibbs JS
    Am J Respir Crit Care Med; 2005 Jun; 171(11):1292-7. PubMed ID: 15750042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
    Hoeper MM; Kramm T; Wilkens H; Schulze C; Schäfers HJ; Welte T; Mayer E
    Chest; 2005 Oct; 128(4):2363-7. PubMed ID: 16236895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.